Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,918 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Ogura M, Hatake K, Tobinai K, Uchida T, Suzuki T, Terui Y, Yokoyama M, Maruyama D, Mori M, Jewell RC, Katsura K, Hotta T. Ogura M, et al. Among authors: mori m. Jpn J Clin Oncol. 2013 May;43(5):466-75. doi: 10.1093/jjco/hyt022. Epub 2013 Feb 28. Jpn J Clin Oncol. 2013. PMID: 23456745 Free PMC article. Clinical Trial.
Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy.
Ogura M, Tobinai K, Hatake K, Uchida T, Kasai M, Oyama T, Suzuki T, Kobayashi Y, Watanabe T, Azuma T, Mori M, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Ono C, Ohata J. Ogura M, et al. Among authors: mori m. Cancer Sci. 2010 Aug;101(8):1840-5. doi: 10.1111/j.1349-7006.2010.01601.x. Epub 2010 Apr 23. Cancer Sci. 2010. PMID: 20491780 Free PMC article. Clinical Trial.
Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
Maruyama D, Watanabe T, Maeshima AM, Nomoto J, Taniguchi H, Azuma T, Mori M, Munakata W, Kim SW, Kobayashi Y, Matsuno Y, Tobinai K. Maruyama D, et al. Among authors: mori m. Int J Hematol. 2010 Dec;92(5):732-43. doi: 10.1007/s12185-010-0728-0. Epub 2010 Dec 1. Int J Hematol. 2010. PMID: 21120644
Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma.
Tobinai K, Ogura M, Kobayashi Y, Uchida T, Watanabe T, Oyama T, Maruyama D, Suzuki T, Mori M, Kasai M, Cronier D, Wooldridge JE, Koshiji M. Tobinai K, et al. Among authors: mori m. Cancer Sci. 2011 Feb;102(2):432-8. doi: 10.1111/j.1349-7006.2010.01809.x. Epub 2011 Jan 12. Cancer Sci. 2011. PMID: 21205069 Free article. Clinical Trial.
Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution.
Fukuhara S, Watanabe T, Munakata W, Mori M, Maruyama D, Kim SW, Kobayashi Y, Taniguchi H, Maeshima AM, Tanosaki R, Matsuno Y, Tobinai K. Fukuhara S, et al. Among authors: mori m. Eur J Haematol. 2011 Nov;87(5):434-40. doi: 10.1111/j.1600-0609.2011.01679.x. Epub 2011 Aug 19. Eur J Haematol. 2011. PMID: 21740461
Diagnosis and evaluation of intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation following reduced-intensity and myeloablative conditioning regimens.
Yamasaki S, Miyagi-Maeshima A, Kakugawa Y, Matsuno Y, Ohara-Waki F, Fuji S, Morita-Hoshi Y, Mori M, Kim SW, Mori S, Fukuda T, Tanosaki R, Shimoda T, Tobinai K, Saito D, Takaue Y, Teshima T, Heike Y. Yamasaki S, et al. Among authors: mori m, mori s. Int J Hematol. 2013 Mar;97(3):421-6. doi: 10.1007/s12185-013-1297-9. Epub 2013 Feb 23. Int J Hematol. 2013. PMID: 23435651 Clinical Trial.
9,918 results